<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510298</url>
  </required_header>
  <id_info>
    <org_study_id>SP-624-221</org_study_id>
    <nct_id>NCT04510298</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia</brief_title>
  <official_title>A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtsei Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirtsei Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of&#xD;
      SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing&#xD;
      acute psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormal Clinical Laboratory Values</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>chemistry, hematology, and urinalysis tests will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Blood Pressure (mmHg)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Blood pressure is measured by sphygmomanometer. Change from baseline measurement will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate (beats per minute)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Pulse rate is measured by sphygmomanometer. Change from baseline measurement will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature (degrees celsius)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Body temperature is measured by oral thermometer. Change from baseline measurement will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight (kilograms)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Body weight is measured by weight scale. Measurement is reported in kilograms. Change from Baseline measurement will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG Heart Rate (beats per minute)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Heart rate is measured by 12-lead electrocardiogram (ECG). Change from Baseline measure will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG RR Interval (seconds)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>RR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG PR Interval (milliseconds)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>PR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG QTcF Interval (milliseconds)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>QTcF is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormal Physical Examination Findings</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with treatment-emergent suicidal ideation or behavior</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>Treatment-emergent suicidal ideation and/or behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with treatment-emergent abnormal movements</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Treatment-emergent abnormal movements will be assessed using a battery of movement assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SP-624</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP-624 oral capsule, 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-624</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>SP-624</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Is willing and able to provide written informed consent to participate in the study.&#xD;
&#xD;
          -  Has an identified reliable informant.&#xD;
&#xD;
          -  Is, in the investigator's opinion, suitable for initiating a washout from the&#xD;
             subject's current antipsychotic regimen, if applicable, and is willing to abstain from&#xD;
             prohibited psychotropic medications in accordance with study requirements.&#xD;
&#xD;
               -  Subjects must meet screening eligibility criteria and be in an inpatient setting&#xD;
                  prior to discontinuing antipsychotic medications.&#xD;
&#xD;
               -  Subject must be able, in the investigator's opinion, to safely discontinue&#xD;
                  prohibited psychotropic medications prior to Baseline without increased&#xD;
                  suicidality.&#xD;
&#xD;
          -  Has a primary diagnosis of schizophrenia based on the Diagnostic and Statistical&#xD;
             Manual 5th edition (DSM-5) criteria and confirmed by Mini International&#xD;
             Neuropsychiatric Interview (MINI) for Psychotic Disorders Studies.&#xD;
&#xD;
          -  Is experiencing an acute exacerbation or relapse of symptoms.&#xD;
&#xD;
          -  Is in generally good physical health, in the investigator's opinion, based on&#xD;
             Screening medical history, physical examination, vital signs, and clinical laboratory&#xD;
             values.&#xD;
&#xD;
          -  Has a body mass index (BMI) between 18 and 40 kg/m2, inclusive.&#xD;
&#xD;
          -  For women of reproductive potential: has a negative serum pregnancy test at Screening&#xD;
             and a negative urine pregnancy test at Baseline.&#xD;
&#xD;
          -  For women of reproductive potential and men with female partners of reproductive&#xD;
             potential: agrees to remain abstinent from sexual intercourse or use adequate and&#xD;
             reliable contraception throughout the study and for at least 30 days after the last&#xD;
             dose of study drug.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Is a woman who is pregnant, breastfeeding, or less than 6 months postpartum at&#xD;
             Screening.&#xD;
&#xD;
          -  Has any primary DSM-5 disorder other than schizophrenia, as confirmed by the MINI.&#xD;
&#xD;
          -  Fails to discontinue prohibited psychotropic medications.&#xD;
&#xD;
          -  Has, in the investigator's opinion, a significant risk of violent or destructive&#xD;
             behavior.&#xD;
&#xD;
          -  Is currently hospitalized involuntarily or incarcerated.&#xD;
&#xD;
          -  Has a history or presence of any clinically significant medical condition, disease, or&#xD;
             surgical history that could, in the investigator's opinion, jeopardize the safety of&#xD;
             the subject or validity of the study data, or interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the study drug.&#xD;
&#xD;
          -  Is, in the investigator's opinion, not a suitable candidate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

